Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Conditions
Interventions
YL-17231
Locations
3
United States
The Lindner Center for Research & Education at The Christ Hospital
Cincinnati, Ohio, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute and Hospital, University of Utah
Salt Lake City, Utah, United States
Start Date
October 24, 2023
Primary Completion Date
October 1, 2025
Completion Date
April 1, 2026
Last Updated
April 9, 2025
NCT07177937
NCT07387068
NCT07360314
NCT07539285
NCT07403721
NCT07524348
Lead Sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions